Jefferies initiates Amgen stock with hold rating on pipeline risk

Jefferies initiated coverage of Amgen with a hold rating and $350 price target, noting a $9.9bn loss-of-exclusivity gap and flagging trial risks (Jefferies cites >30% vomiting risk in MariTide Phase 3 and expects olpasiran could show ~15–20% MACE risk reduction). Gilead reported positive Phase 3 data for a bictegravir+lenacapavir single-tablet HIV regimen (maintained virologic suppression, stable CD4, no emergent resistance) and disclosed acquisitions of Aclx and Arcellx at implied equity values of $7.8bn each; UBS reiterated a $175 PT and the Arcellx deal is expected to close in Q2 2026 with contingent value rights and a termination fee. BofA reiterated Buy on Gilead, citing early prescription momentum for Yeztugo (~5% week-over-week growth) and roughly 90% U.S. insurance coverage.

Analysis

The market is rotating toward deal-driven growth and durable commercial execution, which disproportionately benefits acquirers and takeover targets while penalizing large incumbents with looming loss-of-exclusivity. Expect upward pressure on valuations for small- to mid-cap biotech M&A candidates over the next 6–18 months as strategic buyers compete for scarce assets, tightening CDMO and cell-therapy manufacturing capacity and raising costs for late-stage in‑house development programs.

Amgen is exposed to binary clinical readouts and a multi-year revenue cliff; a negative trial or disappointing uptake would transmit through to suppliers (antibody CDMOs, specialty manufacturers) and to peers by compressing royalty/partnership valuations. Key catalysts that could flip sentiment in the near term are clinical data windows (months–18 months), quarterly earnings guidance revisions, and any unexpected regulatory/payer actions that affect specialty preventive HIV products and PCSK9 economics.

From a positioning standpoint, the market currently underprices integration and CVR execution risk while over-rewarding headline M&A optionality; that creates arbitrage and hedged-option opportunities. If payer coverage and early prescription trends remain stable, investors should expect a 12–24 month revenue ramp but also prepare for a 10–15% downside tail if integration or CVR milestones slip, which is the most probable deal-specific replay risk.

Key Decisions for Investors

• Long GILD (12–18 months): buy shares or a 12–18 month call spread targeting ~+25–35% upside vs ~10–15% downside if the deal stalls; size at 3–5% of portfolio and hedge with a cheap 6–9 month put to limit near-term headline risk.
• Arbitrage long ACLX (until close expected Q2 2026): buy the target at current spread and size as an event-arb (cash-efficient), hedge market beta with a small short S&P or long put on a biotech index; aim to capture 8–12% spread if transaction completes, monitor CVR terms for binary re-rating.
• Short AMGN via put spread (12–24 months): sell/short-term tactical exposure to LOE and binary pipeline risk — enter a Jan‑2027 put spread to cap capital at ~2–3% of portfolio with asymmetric downside capture (target 15–20% move lower if key readouts disappoint).
• Pair trade (rotation): long GILD / short AMGN (6–18 months) to express re-rating into M&A/commercial execution versus LOE- and trial-risked incumbency; keep net delta modest and rebalance on trial readouts or deal milestones.